Aarti Drugs Past Earnings Performance
Past criteria checks 3/6
Aarti Drugs has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 12.4% per year. Aarti Drugs's return on equity is 14.9%, and it has net margins of 6.8%.
Key information
8.9%
Earnings growth rate
9.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.4% |
| Return on equity | 14.9% |
| Net Margin | 6.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aarti Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 26,510 | 1,802 | 1,032 | 0 |
| 30 Sep 23 | 27,090 | 1,802 | 1,013 | 0 |
| 30 Jun 23 | 27,552 | 1,795 | 967 | 0 |
| 31 Mar 23 | 27,161 | 1,663 | 932 | 0 |
| 31 Dec 22 | 26,679 | 1,656 | 895 | 0 |
| 30 Sep 22 | 26,387 | 1,872 | 867 | 0 |
| 30 Jun 22 | 25,306 | 1,910 | 853 | 0 |
| 31 Mar 22 | 24,886 | 2,050 | 841 | 0 |
| 31 Dec 21 | 22,961 | 2,014 | 822 | 0 |
| 30 Sep 21 | 21,916 | 2,111 | 812 | 0 |
| 30 Jun 21 | 21,901 | 2,438 | 817 | 0 |
| 31 Mar 21 | 21,548 | 2,804 | 815 | 0 |
| 31 Dec 20 | 21,027 | 2,876 | 808 | 0 |
| 30 Sep 20 | 20,459 | 2,474 | 783 | 0 |
| 30 Jun 20 | 19,453 | 2,044 | 717 | 0 |
| 31 Mar 20 | 18,061 | 1,414 | 710 | 0 |
| 31 Dec 19 | 18,156 | 1,100 | 728 | 0 |
| 30 Sep 19 | 17,222 | 1,031 | 703 | 0 |
| 30 Jun 19 | 15,921 | 888 | 679 | 0 |
| 31 Mar 19 | 15,609 | 898 | 665 | 0 |
| 31 Dec 18 | 14,136 | 863 | 634 | 0 |
| 30 Sep 18 | 13,689 | 887 | 635 | 0 |
| 30 Jun 18 | 13,407 | 943 | 630 | 0 |
| 31 Mar 18 | 12,436 | 823 | 618 | 0 |
| 31 Dec 17 | 11,592 | 790 | 613 | 0 |
| 30 Sep 17 | 11,340 | 735 | 590 | 0 |
| 30 Jun 17 | 11,569 | 721 | 580 | 0 |
| 31 Mar 17 | 11,952 | 818 | 557 | 0 |
| 31 Dec 16 | 12,102 | 785 | 527 | 0 |
| 30 Sep 16 | 11,856 | 776 | 509 | 0 |
| 30 Jun 16 | 11,431 | 713 | 486 | 0 |
| 31 Mar 16 | 11,349 | 687 | 467 | 0 |
| 31 Dec 15 | 11,101 | 686 | 749 | 0 |
| 30 Sep 15 | 11,047 | 744 | 731 | 0 |
| 30 Jun 15 | 11,180 | 774 | 414 | 0 |
| 31 Mar 15 | 10,943 | 773 | 394 | 0 |
| 31 Dec 14 | 10,868 | 807 | 690 | 0 |
| 30 Sep 14 | 10,490 | 721 | 679 | 0 |
| 30 Jun 14 | 10,109 | 662 | 671 | 0 |
| 31 Mar 14 | 9,699 | 608 | 657 | 0 |
| 31 Dec 13 | 9,083 | 526 | 576 | 0 |
| 30 Sep 13 | 8,851 | 494 | 573 | 0 |
| 30 Jun 13 | 8,535 | 482 | 556 | 0 |
Quality Earnings: 524348 has high quality earnings.
Growing Profit Margin: 524348's current net profit margins (6.8%) are higher than last year (6.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524348's earnings have grown by 8.9% per year over the past 5 years.
Accelerating Growth: 524348's earnings growth over the past year (8.8%) is below its 5-year average (8.9% per year).
Earnings vs Industry: 524348 earnings growth over the past year (8.8%) did not outperform the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 524348's Return on Equity (14.9%) is considered low.